Ark Therapeutics Group PLC (AKT.L)

AKT.L

About

Ark Therapeutics Group plc is engaged in the provision of contract development and manufacturing services to the pharmaceutical and biotech industry. The Company’s business activity includes the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and... (more)

Buy/Sell

No analyst recommendations are available for AKT.L.

» Analyst Consensus

Overall

Beta:	0.42
Market Cap (Mil.):	£0.96
Shares Outstanding (Mil.):	209.28
Dividend:	--
Yield (%):	--

Financials

	AKT.L	Industry	Sector
P/E (TTM):	--	32.01	32.18
EPS (TTM):	-0.06	--	--
ROI:	-130.89	19.61	18.91
ROE:	-142.32	20.45	19.87

Latest News about AKT.L

UPDATE 1-Ark Therapeutics sells two units; shares plunge

* Shares fall as much as 61 pct (Adds background; updates share movement)

15 Mar 2013

Ark Therapeutics sells two units; shares plunge

March 15 - Healthcare specialist Ark Therapeutics Group Plc said it sold two units after a process to sell itself attracted only one bidder, which later withdrew its offer.

15 Mar 2013

Ark Therapeutics puts itself on the block

Jan 30 - Ark Therapeutics Group Plc said it had begun a formal sale process and appointed an advisor to evaluate strategic options after fund-raising talks collapsed.

30 Jan 2013

BRIEF-Ark Therapeutics puts itself up for sale

LONDON, Jan 30 - Ark Therapeutics Group PLC : * Grp - strategic review update * Proposed funding options have not at this stage reached fruition * Options include securing long term strategic partners, including an offer

30 Jan 2013

» More AKT.L News

Earnings vs. Estimates

Analyst Research Reports

Report Title	Price
Thomson Reuters Stock Report - ARK THERAPEUTICS GROUP PLC (AKT-LN) Provider: Thomson Reuters Stock Report	$25.00 Buy
Ark Therapeutics Group PLC: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy
Wright Investors Service Comprehensive Report for Ark Therapeutics Group Plc Provider: Wright Reports	$472.00 Buy
Ark Therapeutics Group plc (AKT) - Medical Equipment - Deals and Alliances Profile Provider: GlobalData	$250.00 Buy
Ark Therapeutics Group plc (AKT) - Financial and Strategic SWOT Analysis Review Provider: GlobalData	$125.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.